Myriam Heiman, a renowned molecular neurobiologist and geneticist, has been appointed as the new director of MIT's Picower Institute for Learning and Memory, effective July 1. This appointment marks a significant transition for the institute, as Heiman takes over from Li-Huei Tsai, who has led the institute for 16 years. Heiman's expertise lies in studying neurodegenerative diseases affecting the brain's basal ganglia, including Huntington's and Parkinson's diseases. Her research employs cutting-edge techniques, such as single-cell genomics and her own invention, translating ribosome affinity purification, to unravel the molecular changes leading to cell death in these diseases.
Heiman's appointment is a testament to her exceptional scientific contributions and leadership within MIT. Dean Nergis Mavalvala praises her research, highlighting its depth and scope in understanding the vulnerability of specific brain cell types to diseases like Huntington's. Mavalvala believes that Heiman's leadership will be instrumental in the Picower Institute's future endeavors.
Heiman herself expresses her honor and enthusiasm for the new role, emphasizing her commitment to supporting the institute's scientists and trainees in their pursuit of groundbreaking discoveries. Her research has already yielded significant findings, including an in vivo screening of mouse genes that identified genes crucial for neuron survival in Huntington's disease.
Furthermore, Heiman's work has shed light on errant immune responses in neurons and blood vessels, contributing to disease progression. Her collaboration with Manolis Kellis resulted in the creation of a cellular atlas of the brain's vasculature, providing valuable insights into neurodegenerative and psychiatric disorders. Heiman's research has also explored overlaps between ALS and frontotemporal dementia, offering potential therapeutic targets.
Heiman's dedication to teaching and mentoring is equally impressive. She has received awards for excellence in graduate and undergraduate mentoring, and her commitment to caring for students has been recognized by MIT's Office of Graduate Education. Beyond her academic achievements, Heiman serves on editorial boards and the scientific advisory board of the Huntington's Disease Foundation, demonstrating her commitment to advancing research in this field.
In conclusion, Myriam Heiman's appointment as the new director of the Picower Institute signifies a new era of leadership and scientific excellence. Her expertise, research achievements, and dedication to mentorship position her as a valuable asset to MIT and the broader scientific community. As she embarks on this new role, Heiman's enthusiasm and commitment to transformative research will undoubtedly shape the institute's future endeavors.
